---
figid: PMC7107758__nihms-1029545-f0004
figlink: pmc/articles/PMC7107758/figure/F4/
number: F4
caption: Examples of mechanisms of resistance to BRAF and MEK inhibitors in BRAF-V600E
  melanoma are depicted.,,,,, Inhibitors shown as blue circles. Yellow stars denote
  mutants present prior to drug exposure; red stars denote secondary mutations that
  can happen as a result of inhibitor treatment. Red arrows indicate upregulation
  of protein expression and/or other cellular pathways. Resistance can occur as a
  result of changes within the ERK pathway itself, including BRAF upregulation; upregulation
  and heterodimerization of other Raf isoforms or BRAF splice forms; activation of
  MEK by MLK; MEK mutations; upregulation or mutation of Ras isoforms; and upregulation
  of receptor tyrosine kinases. Suppression of negative feedback in the ERK pathway,
  for example, through mutation/loss of NF1, can result in resistance. Resistance
  can also arise by kinome remodeling at the RTK level and upregulation of alternate
  signaling pathways like PI3K/Akt/mTOR. Changes in the tumor microenvironment, as
  well as metabolic reprogramming to promote glycolysis or MITF overexpression, can
  also overcome ERK pathway inhibition
pmcid: PMC7107758
papertitle: Targeting ERK beyond the boundaries of the kinase active site in melanoma.
reftext: Rachel M. Sammons, et al. Mol Carcinog. ;58(9):1551-1570.
pmc_ranked_result_index: '4032'
pathway_score: 0.9766453
filename: nihms-1029545-f0004.jpg
figtitle: Resistance mechanisms to BRAF and MEK inhibitors in BRAF-V600E melanoma
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7107758__nihms-1029545-f0004.html
  '@type': Dataset
  description: Examples of mechanisms of resistance to BRAF and MEK inhibitors in
    BRAF-V600E melanoma are depicted.,,,,, Inhibitors shown as blue circles. Yellow
    stars denote mutants present prior to drug exposure; red stars denote secondary
    mutations that can happen as a result of inhibitor treatment. Red arrows indicate
    upregulation of protein expression and/or other cellular pathways. Resistance
    can occur as a result of changes within the ERK pathway itself, including BRAF
    upregulation; upregulation and heterodimerization of other Raf isoforms or BRAF
    splice forms; activation of MEK by MLK; MEK mutations; upregulation or mutation
    of Ras isoforms; and upregulation of receptor tyrosine kinases. Suppression of
    negative feedback in the ERK pathway, for example, through mutation/loss of NF1,
    can result in resistance. Resistance can also arise by kinome remodeling at the
    RTK level and upregulation of alternate signaling pathways like PI3K/Akt/mTOR.
    Changes in the tumor microenvironment, as well as metabolic reprogramming to promote
    glycolysis or MITF overexpression, can also overcome ERK pathway inhibition
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K1
  - MAP2K2
  - BRAF
  - EGF
  - NRG1
  - HGF
  - GRB2
  - SOS1
  - SOS2
  - HRAS
  - KRAS
  - NRAS
  - NF1
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - PTEN
  - ARAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - MTOR
  - MAPK3
  - MAPK1
  - MITF
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: EGF,
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: e.g.HGF,EGF,NRG1
  symbol: NRG1
  source: hgnc_symbol
  hgnc_symbol: NRG1
  entrez: '3084'
- word: e.g.HGF,EGF,NRG1
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: HGF,
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: NRG1
  symbol: NRG1
  source: hgnc_symbol
  hgnc_symbol: NRG1
  entrez: '3084'
- word: Grb-2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: C-Raf
  symbol: CRAF
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: C-Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: C-Raf
  symbol: CRAF
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MITF
  symbol: MITF
  source: hgnc_symbol
  hgnc_symbol: MITF
  entrez: '4286'
chemicals: []
diseases: []
figid_alias: PMC7107758__F4
redirect_from: /figures/PMC7107758__F4
figtype: Figure
---
